|
C16ORF57 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.6680000004008E-07 |
| Normal-vs-Stage3 |
1.65356617287671E-12 |
| Normal-vs-Stage4 |
1.84540160930169E-11 |
| Stage1-vs-Stage2 |
6.232400E-01 |
| Stage1-vs-Stage3 |
7.720200E-01 |
| Stage1-vs-Stage4 |
4.801800E-02 |
| Stage2-vs-Stage3 |
7.970600E-01 |
| Stage2-vs-Stage4 |
8.337900E-02 |
| Stage3-vs-Stage4 |
4.917600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.16119999971876E-07 |
| Normal-vs-Asian |
4.07620048825663E-10 |
| Caucasian-vs-AfricanAmerican |
6.777000E-01 |
| Caucasian-vs-Asian |
9.715600E-01 |
| AfricanAmerican-vs-Asian |
6.798000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62481139653892E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
8.335200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
3.05444558534873E-12 |
| Normal-vs-Age(81-100Yrs) |
4.00769999999717E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.464200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.816800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.577800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.585800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.107200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.205400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.460000E-01 |
| Classical-VS-Follicular |
3.314500E-02 |
| Classical-VS-Other |
2.653200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.560360E-02 |
| Tall-VS-Other |
8.533600E-02 |
| Tall-VS-Normal |
2.31650254534088E-11 |
| Follicular-VS-Other |
8.133800E-01 |
| Follicular-VS-Normal |
2.01009999756252E-08 |
| Other-VS-Normal |
1.977280E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62436730732907E-12 |
| Normal-vs-N1 |
2.46260000169585E-08 |
| N0-vs-N1 |
6.424800E-01 |
|
|
